{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-070316","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2026-06-22T10:05:49+00:00","discovered_at":"2026-06-22T10:10:00.336333+00:00","generated_at":"2026-06-22T10:10:26.412001+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Unicycive stockholders re-elect three directors and ratify auditor at 2026 annual meeting","bullets":["Directors elected: Dr. Shalabh Gupta (8.13M for, 174k withhold), Dr. Sandeep Laumas (7.70M for, 610k withhold), D. Sarawati Kenkare-Mitra (7.51M for, 795k withhold).","Ratification of Grassi & Co. as auditor for FY 2026 passed with 14.67M for, 287k against, 10k abstentions.","14,964,159 shares represented at the meeting, constituting a quorum.","Broker non-votes totaled approximately 6.66M shares on each director election."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-070316","json":"https://secwatch.observer/filing/0001213900-26-070316.json","markdown":"https://secwatch.observer/filing/0001213900-26-070316.md","text":"https://secwatch.observer/filing/0001213900-26-070316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026070316/0001213900-26-070316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026070316/ea0295382-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T10:10:26.412001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31fd24dcddfbbaf6dc9913662b5f55e5f16768c5","claim":"Unicycive Therapeutics, Inc. shareholders approved Ratification of appointment of Grassi & Co. CPAs, P.C. as independent registered public accounting firm for fiscal year 2026 at the 2025-06-19 meeting.","evidence_excerpt":"The appointment of Grassi & Co. CPAs, P.C. as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 14,667,242 286,958 9,928 31","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026070316/0001213900-26-070316-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2025-06-19"}],"fact_type":"shareholder_vote"},{"claim_id":"ef3e142c221fcb1dc97dcf18e330b93d72b97561","claim":"Unicycive Therapeutics, Inc. shareholders approved Election of three nominees for director at the 2025-06-19 meeting.","evidence_excerpt":"On June 19, 2025, Unicycive Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”).","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026070316/0001213900-26-070316-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2025-06-19"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}